Oral application of 1,7-dimethylxanthine (paraxanthine) attenuates the formation of experimental cholestatic liver fibrosis

Hepatology Research

Volumn 41, Issue 11, 2011, Pages 1094-1109

  Klemmer, Ildikó ^d   Yagi, Shintaro ^b,c   Gressner, Olav A ^a,d  

^a Wisplinghoff Medical Laboratories   (Germany)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

^c RWTH AACHEN UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

1,7 dimethylxanthine; Caffeine; Fibrogenesis; Paraxanthine; Smad signaling; Transforming growth factor

Indexed keywords

COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; EOSIN; HEMATOXYLIN; MALONALDEHYDE; PARAXANTHINE; SMAD2 PROTEIN; SMAD3 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT LIGATION; CELL LYSATE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IN VITRO STUDY; IN VIVO STUDY; INTRAHEPATIC CHOLESTASIS; LIPID PEROXIDATION; LIQUID CHROMATOGRAPHY; LIVER; LIVER CELL; LIVER FIBROSIS; MALE; MASS SPECTROMETRY; NONHUMAN; OXIDATIVE STRESS; PILOT STUDY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; REPORTER GENE; SHAM PROCEDURE; SPRAGUE DAWLEY RAT; STAINING; STELLATE CELL; WESTERN BLOTTING;

EID: 84861179585     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00856.x     Document Type: Article

References (61)

1. Abreu JG, Ketpura NI, Reversade B, De Robertis EM. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat Cell Biol 2002; 4: 599-604.
2. Gressner OA, Lahme B, Siluschek M, Rehbein K, Weiskirchen R, Gressner AM. Connective tissue growth factor is a Smad2 regulated amplifier of transforming growth factor beta actions in hepatocytes-but without modulating bone morphogenetic protein 7 signaling. Hepatology 2009; 49 (6): 2021-30.
3. George J, Tsutsumi M. siRNA-mediated knockdown of connective tissue growth factor prevents Nnitrosodimethylamine-induced hepatic fibrosis in rats. Gene Ther 2007; 14: 790-803.
4. Li G, Xie Q, Shi Y, Li D, Zhang M, Jiang S, Zhou H, Lu H, Jin Y. Inhibition of connective tissue growth factor by siRNA prevents liver fibrosis in rats. J Gene Med 2006; 8: 889-900.
5. Boag JM, Beesley AH, Firth MJ, et al. High expression of connective tissue growth factor in pre-B acute lymphoblastic leukaemia. Br J Haematol 2007; 138: 740-8.
6. Gressner OA, Gressner AM. Connective tissue growth factor: a fibrogenic master switch in fibrotic liver diseases. Liver Int 2008; 28: 1065-79.
7. Hayashi N, Kakimuma T, Soma Y, Grotendorst GR, Tamaki K, Harada M, Igarashi A. Connective tissue growth factor is directly related to liver fibrosis. Hepatogastroenterology 2002; 49 (43): 133-5.
8. Kidd M, Modlin IM, Shapiro MD, Camp RL, Mane SM, Usinger W, Murren JR. CTGF, intestinal stellate cells and carcinoid fibrogenesis. World J Gastroenterol 2007; 13: 5208-16.
9. Liu LY, Han YC, Wu SH, Lv ZH. Expression of connective tissue growth factor in tumor tissues is an independent predictor of poor prognosis in patients with gastric cancer. World J Gastroenterol 2008; 14: 2110-4.
10. Mullis TC, Tang X, Chong KT. Expression of connective tissue growth factor (CTGF/CCN2) in head and neck squamous cell carcinoma. J Clin Pathol 2008; 61: 606-10.
11. Munemasa S, Sakai A, Kuroda Y et al. Connective tissue growth factor is an indicator of bone involvement in multiple myeloma, but matrix metalloproteinase-9 is not. Br J Haematol 2007; 139: 41-50.
12. Paradis V, Dargere D, Vidaud M et al. Expression of connective tissue growth factor in experimental rat and human liver fibrosis. Hepatology 1999; 30 (4): 968-76.
13. Rachfal AW, Brigstock DR. Connective tissue growth factor (CTGF/CCN2) in hepatic fibrosis. Hepatol Res 2003; 26 (1): 1-9.
14. Gressner AM, Weiskirchen R, Breitkopf K, Dooley S. Roles of TGF-beta in hepatic fibrosis. Front Biosci 2002; 7: d793-807.
15. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134 (6): 1655-69.
16. Gressner OA, Rizk MS, Kovalenko E, Weiskirchen R, Gressner AM. Changing the pathogenetic roadmap of liver fibrosis? Where did it start; where will it go? J Gastroenterol Hepatol 2008; 23 (7 Pt 1): 1024-35.
17. Braun L, Gruppuso P, Mikumo R, Fausto N. Transforming growth factor beta 1 in liver carcinogenesis: messenger RNA expression and growth effects. Cell Growth Differ 1990; 1 (3): 103-11.
18. Modi AA Feld JJ, Park Y et al. Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology 2010; 51 (1): 201-9.
19. Ruhl CE, Everhart JE. Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2005; 128 (1): 24-32.
20. Ruhl CE, Everhart JE. Coffee and tea consumption are associated with a lower incidence of chronic liver disease in the United States. Gastroenterology 2005; 129 (6): 1928-36.
21. Gressner OA, Lahme B, Rehbein K, Siluschek M, Weiskirchen R, Gressner AM. Pharmacological application of caffeine inhibits TGF-beta-stimulated connective tissue growth factor expression in hepatocytes via PPARgamma and SMAD2/3-dependent pathways. J Hepatol 2008; 49: 758-67.
22. Gressner OA, Lahme B, Siluschek M, Gressner AM. Identification of paraxanthine as the most potent caffeinederived inhibitor of connective tissue growth factor expression in liver parenchymal cells. Liver Int 2009; 29: 886-97.
23. Leask A. The Starbuck stops here: it's a Smad world. J Cell Commun Signal 2008; 2 (1-2): 1-2.
24. Schafer S, Zerbe O, Gressner AM. The synthesis of proteoglycans in fat-storing cells of rat liver. Hepatology 1987; 7: 680-7.
25. Fehrenbach H, Weiskirchen R, Kasper M, Gressner AM. Up-regulated expression of the receptor for advanced glycation end products in cultured rat hepatic stellate cells during transdifferentiation to myofibroblasts. Hepatology 2001; 34: 943-52.
26. Seglen PO. Preparation of isolated rat liver cells. Methods Cell Biol 1976; 13: 29-83.
27. Gressner AM, Lahme B, Roth S. Attenuation of TGF-betainduced apoptosis in primary cultures of hepatocytes by calpain inhibitors. Biochem Biophys Res Commun 1997; 231 (2): 457-62.
28. Gressner AM, Pfeiffer T. Preventive effects of acute inflammation on liver cell necrosis and inhibition of heparan sulphate synthesis in hepatocytes. J Clin Chem Clin Biochem 1986; 24: 821-9.
29. Kountouras J, Billing BH, Scheuer PJ. Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. Br J Exp Pathol 1984; 65: 305-11.
30. Borkham-Kamphorst E, Stoll D, Gressner AM, Weiskirchen R. Antisense strategy against PDGF B-chain proves effective in preventing experimental liver fibrogenesis. Biochem Biophys Res Commun 2004; 321 (2): 413-23.
31. Gressner OA, Lahme B, Demirci I, Gressner AM, Weiskirchen R. Differential effects of TGF-beta on connective tissue growth factor (CTGF/CCN2) expression in hepatic stellate cells and hepatocytes. J Hepatol 2007; 47: 699-710.
32. Gressner AM, Yagmur E, Lahme B, Gressner O, Stanzel S. Connective tissue growth factor in serum as a new candidate test for assessment of hepatic fibrosis. Clin Chem 2006; (9): 1815-7.
33. Hata K, Tolba RH, Wei L et al. Impact of polysol, a newly developed preservation solution, on cold storage of steatotic rat livers. Liver Transpl 2007; 13: 114-21.
34. Minor T, Kotting M. Gaseous oxygen for hypothermic preservation of predamaged liver grafts: fuel to cellular homeostasis or radical tissue alteration? Cryobiology 2000; 40: 182-6.
35. Paradis V, Dargere D, Bonvoust F, Vidaud M, Segarini P, Bedossa P. Effects and regulation of connective tissue growth factor on hepatic stellate cells. Lab Invest 2002; 82: 767-74.
36. Niki E. Lipid peroxidation products as oxidative stress biomarkers. Biofactors 2008; 34: 171-80.
37. Poli G. Pathogenesis of liver fibrosis: role of oxidative stress. Mol Aspects Med 2000; 21 (3): 49-98.
38. Lelo A, Kjellen G, Birkett DJ, Miners JO. Paraxanthine metabolism in humans: determination of metabolic partial clearances and effects of allopurinol and cimetidine. J Pharmacol Exp Ther 1989; 248 (1): 315-9.
39. Benowitz NL, Jacob P 3rd, Mayan H, Denaro C. Sympathomimetic effects of paraxanthine and caffeine in humans. Clin Pharmacol Ther 1995; 58: 684-91.
40. Bortolotti A, Jiritano L, Bonati M. Pharmacokinetics of paraxanthine, one of the primary metabolites of caffeine, in the rat. Drug Metab Dispos 1985; 13: 227-31.
41. Arnaud MJ, Welsch C. Metabolism of [1-Me-14C]-paraxanthine in the rat: identification of a new metabolite. Experientia 1979; 35: 946.
42. Tang-Liu DD, Williams RL, Riegelman S. Disposition of caffeine and its metabolites in man. J Pharmacol Exp Ther 1983; 224: 180-5.
43. Labedzki A, Buters J, Jabrane W, Fuhr U. Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2. Biochem Pharmacol 2002; 63: 2159-67.
44. Nelson DL, Cox MM. Lehninger Principles of Biochemistry. Basingstoke (UK): Palgrave Macmillan; Freeman, 2008.
45. Salway JG. Metabolism at a Glance. Hoboken (NJ, USA): Wiley-Blackwell, 2004.
46. Arnaud MJ, Enslen M. 1992) The role of paraxanthine in mediating physiological effects of caffeine. 4th International Conference in Coffee Sciences, San Francisco, July 14 to 19 1991, Proceedings ASIC, Paris, 71-79.
47. Probst RJ, Lim JM, Bird DN, Pole GL, Sato AK, Claybaugh JR. Gender differences in the blood volume of conscious Sprague-Dawley rats. J Am Assoc Lab Anim Sci 2006; 45 (2): 49-52.
48. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008; 88: 125-72.
49. Lindert S, Wickert L, Sawitza I, et al. Transdifferentiationdependent expression of alpha-SMA in hepatic stellate cells does not involve TGF-beta pathways leading to coinduction of collagen type I and thrombospondin-2. Matrix Biol 2005; 24: 198-207.
50. Uemura M, Swenson ES, Gaça MD, Giordano FJ, Reiss M, Wells RG. Smad2 and Smad3 play different roles in rat hepatic stellate cell function and alpha-smooth muscle actin organization. Mol Biol Cell 2005; 16 (9): 4214-24.
51. Browning SL, Tarekegn A, Bekele E, Bradman N, Thomas MG.CYP1A2 is more variable than previously thought: a genomic biography of the gene behind the human drugmetabolizing enzyme. Pharmacogenet Genomics 2010; 20: 647-64.
52. Kudo M, Moteki T, Sasaki T et al. Functional characterization of human xanthine oxidase allelic variants. Pharmacogenet Genomics 2008; 18: 243-51.
53. Sim E, Lack N, Wang CJ, et al. Arylamine Nacetyltransferases: structural and functional implications of polymorphisms. Toxicology 2008; 254: 170-83.
54. Sheen-Chen SM, Eng HL, Hung KS. Altered serum transforming growth factor-beta1 and monocyte chemoattractant protein-1 levels in obstructive jaundice. World J Surg 2004; 28: 967-70.
55. Yamano T, Hirai R, Hato S, Uemura T, Shimizu N. Delayed liver regeneration with negative regulation of hepatocyte growth factor and positive regulation of transforming growth factor-beta1 mRNA after portal branch ligation in biliary obstructed rats. Surgery 2002; 131: 163-71.
56. Deneme MA, Ok E, Akcan A, Akyildiz H, Soyuer I, Muhtaroglu S. Single dose of anti-transforming growth factor-beta1 monoclonal antibody enhances liver regeneration after partial hepatectomy in biliary-obstructed rats. J Surg Res 2006; 136: 280-7.
57. Zhang Y, Chang C, Gehling DJ, Hemmati-Brivanlou A, Derynck R. Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase. Proc Natl Acad Sci USA 2001; 98 (3): 974-9.
58. Wicks SJ, Grocott T, Haros K, Maillard M, ten Dijke P, Chantry A. Reversible ubiquitination regulates the Smad/ TGF-beta signalling pathway. Biochem Soc Trans 2006; 34 (Pt 5): 761-3.
59. Massagué J, Blain SW, Lo RS. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 2000; 103: 295-309.
60. Qin BY, Lam SS, Correia JJ, Lin K. Smad3 allostery links TGF-beta receptor kinase activation to transcriptional control. Genes Dev 2002; 16: 1950-63.
61. Ebisawa T, Fukuchi M, Murakami G et al. Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation. J Biol Chem 2001; 276 (16): 12477-80.